Company Overview and News
EDMONTON, Alberta, June 18, 2018 (GLOBE NEWSWIRE) -- Capital Power Corporation (TSX:CPX) (the Corporation and together with its subsidiaries, Capital Power) announced today that after having taken into account all Election Notices following the June 15, 2018 conversion deadline, in respect of the Cumulative Rate Reset Preference Shares, Series 5 (Series 5 Shares) tendered for conversion into Cumulative Floating Rate Preference Shares, Series 6 (Series 6 Shares), the holders of Series 5 Shares were not entitled to convert their shares.
EDMONTON, Alberta, June 07, 2018 (GLOBE NEWSWIRE) -- Capital Power is pleased to announce it is ranked among Corporate Knights’ 2018 Best 50 Corporate Citizens in Canada. Capital Power ranked 21st overall up from 40th in 2017.
EDMONTON, Alberta, May 31, 2018 (GLOBE NEWSWIRE) -- Capital Power Corporation (TSX:CPX) (the Corporation and together with its subsidiaries, Capital Power) announced today that it has notified registered shareholders of its Cumulative Rate Reset Preference Shares, Series 5 (Series 5 Shares) (TSX:CPX.PR.E) of the Conversion Privilege and Dividend Rate Notice.
EDMONTON, Alberta, May 01, 2018 (GLOBE NEWSWIRE) -- The annual meeting of shareholders (annual meeting) for Capital Power Corporation (TSX:CPX) (Capital Power or the Company) was held on April 27, 2018 in Edmonton, Alberta. Each of the matters voted upon at the annual meeting is discussed in detail in the Company’s Management Proxy Circular dated March 1, 2018 and available on the Company’s website at: www.
EDMONTON, Alberta, April 30, 2018 (GLOBE NEWSWIRE) -- Capital Power Corporation (Capital Power, or the Company) (TSX:CPX) today released financial results for the quarter ended March 31, 2018.
EDMONTON, Alberta, April 27, 2018 (GLOBE NEWSWIRE) -- The Board of Directors for Capital Power Corporation (TSX:CPX) (Capital Power) declared a dividend of $0.4175 per share on the outstanding common shares for the quarter ending June 30, 2018. The dividend is payable on July 31, 2018 to shareholders of record at the close of business on June 29, 2018.
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
Silicon Investor Message Boards
This table lists all message boards related to TSX:CPX / Capital Power Corporatio on message board site Silicon Investor.
|Celator Pharmaceuticals - CPXX||Loews Cineplex Entertainment (LCX) (was CPX)|